Growth hormone resistance in acute myocardial infarction
DOI:
https://doi.org/10.5457/ams.v41i1.262Keywords:
growth hormone (GH), insulin like growth factor one (IGF-1), insulin, infarctionAbstract
Background and aim: Hormonal and immunological aspects of acute myocardial infarction (AMI) are in the past decade in focus of interest of researchers. We investigated concentrations of insulin like growth factor 1 (IGF-1), growth hormone (GH), insulin and markers of insulin resistance as like as inflammatory markers in order to find out their role and relationship in AMI.
Material and methods: A prospective study was performed at University Clinical Center Tuzla from January to October 2010. Study group was consisted of 75 patients with AMI. There were 30 healthy controls. Blood samples were taken within first 24 hours of admission and analyzed for GH, IGF-1 and insulin at the Department of Nuclear Medicine. Glucose, glycolised hemoglobin HbA1c, C-reactive protein (CRP), fibrinogen etc. were analyzed by standard methods at Biochemistry unit.
Results: Median of GH in the study group (0,96) was higher than in controls (0,26); p <0.001. Difference in median’s concentrations of IGF-1 between AMI and controls was also significant (123 vs. 132 respectively; p< 0,05) as like as IGF-1/GH ratio (p <0.001). Concentration of insulin was higher in study (9,5) than in control group (7,1), but without statistical significance. Despite this, we found out significant difference between concentrations of glucose, HOMA-IR and HbA1C among groups. Levels of CRP and fibrinogen were significantly higher in AMI. Simple linear correlation analysis showed positive correlation between GH and CRP (R 0,350255, p< 0,005).
Conclusions: GH resistance in AMI (Low IGF-1/GH) is probably result of inflammatory/immunological response and therefore could be prognostic marker.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
